Helsinn Group and Glenmark Pharmaceuticals enter into an exclusive licensing agreement for launch of AKYNZEO® in India and Nepal
April 04, 2018 04:30 ET
|
Helsinn Healthcare S.A.
Helsinn Group and Glenmark Pharmaceuticals enter into an exclusive licensing agreement for launch of AKYNZEO® in India and Nepal AKYNZEO®, containing netupitant 300mg and palonosetron 0.5mg, is...
Helsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership Awards
March 26, 2018 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership Awards For the fourth year running, Helsinn Advanced Synthesis has won first place in all core award categories...
Helsinn Group announces agreement to acquire worldwide rights to Valchlor/Ledaga, an approved and marketed alkylating agent for topical treatment of mycosis fungoides type cutaneous T-cell lymphoma
March 21, 2018 04:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides-type cutaneous T-cell...
Helsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV vs NEPA Oral for the prevention of chemotherapy induced nausea and vomiting (CINV) in Women with Breast Cancer
March 20, 2018 04:31 ET
|
Helsinn Healthcare S.A.
Lugano, Switzerland, March 20, 2018 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announced that the first patient has been enrolled in a Phase 3b...
Helsinn Healthcare S.A.: Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology
March 01, 2018 08:36 ET
|
Helsinn Healthcare S.A.
Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology Eleven finalists have been selected from a strong roster of talent to compete at the...
Helsinn Files Petition for Writ of Certiorari for Supreme Court Review Regarding Patent Covering Aloxi® in the US Market
February 28, 2018 15:14 ET
|
Helsinn Healthcare S.A.
Helsinn Files Petition for Writ of Certiorari for Supreme Court Review Regarding Patent Covering Aloxi® in the US Market Lugano, Switzerland, and Woodcliff Lake, N.J., February 28, 2018 - In...
Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics (HTU)
February 27, 2018 12:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics (HTU) Lugano, Switzerland February 27, 2018 - Helsinn, a Swiss pharmaceutical group...
Helsinn Healthcare S.A.: Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement
January 30, 2018 04:00 ET
|
Helsinn Healthcare S.A.
Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement Investigating the role of pharmacological inhibitors in kidney cancer Lugano, Switzerland, January 30, 2018 -...
Helsinn: US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi® in the US Market Are Invalid
January 17, 2018 13:41 ET
|
Helsinn Healthcare S.A.
US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi® in the US Market Are Invalid Lugano,...
Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)
January 11, 2018 09:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML) Lugano, Switzerland...